# A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

> **NCT01685892** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT01685892
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-29
- **Primary completion:** 2018-05-21
- **Final completion:** 2019-08-23
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685892, "A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01685892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*